Asset profile
Beperminogene perplasmid (HGF plasmid) · Collategene
Gene therapy / editing
Evidence outlook · lead readout
NCT04274049 · Arterial Occlusive Disease, Ischemia, Ulcers, Peripheral Vascular Disease
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT04274049: This was a randomized, quadruple-blind, placebo-controlled trial in 242 patients using complete ulcer healing, a direct clinical outcome, as its primary measure. Complete healing occurred in 70 of 161 treated patients versus 15 of 81 on placebo, a 26.1-percentage-point difference (P<.001), meeting the primary endpoint.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 18 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Beperminogene Perplasmid (HGF Plasmid) (Collategene): this drug | Phase 3 | Gene therapy / editing | Hepatocyte growth factor (HGF), HGF (hepatocyte growth factor) | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Bempedoic Acid (Nexletol) | Approved | Small molecule | Adenosine Triphosphate-Citrate Lyase Inhibitor, ATP citrate lyase | ||
| Bempedoic Acid / Ezetimibe | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | ||
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | ||
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | ||
| Icosapent Ethyl (Vascepa) | Approved | Small molecule | Omega-3 fatty acid (EPA) | ||
| Inclisiran (Leqvio) | Approved | RNA / oligonucleotide | PCSK9 | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Lomitapide (Juxtapid) | Approved | Small molecule | MTP | ||
| Nexlizet | Approved | — | — | ||
| Olezarsen (Tryngolza) | Approved | RNA / oligonucleotide | APOC3 | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.